Finding 1146536 (2024-017)

Significant Deficiency
Requirement
P
Questioned Costs
-
Year
2024
Accepted
2025-07-02
Audit: 361368
Auditor: Dwc

AI Summary

  • Core Issue: Solvista Health did not include expenditures for two federal awards in its SEFA for the year ending June 30, 2023.
  • Impacted Requirements: This violates 2 CFR 200.302(b)(4) and 2 CFR Part 200.510, which require accurate reconciliation of federal awards and preparation of a complete SEFA.
  • Recommended Follow-Up: Implement internal controls for reconciling federal awards and expenditures, ensure accurate SEFA preparation, and provide training for staff on compliance requirements.

Finding Text

Criteria or Specific Requirement: 2 CFR 200.302(b)(4) requires non-federal entities to maintain effective internal control over federal programs. Specifically, the organization must reconcile its federal awards with expenditures incurred and revenue received. Additionally, 2 CFR Part 200.510(b)(1-6) mandates that a Schedule of Expenditures of Federal Awards (SEFA) be prepared for each fiscal year in accordance with the applicable federal regulations. The SEFA must include, at a minimum, total federal awards expended for each individual federal program and must accurately report all federal expenditures received and expended during the fiscal year. Condition and Context: During our audit procedures performed over the current year SEFA, it was noted that Solvista Health improperly excluded expenditures for two federal awards from its June 30, 2023 SEFA. Questioned Costs: N/A Cause: Solvista Health’s accounting and internal control systems were not designed and implemented to ensure reconciliation of federal awards with expenditures and revenue, and the preparation of an accurate SEFA. Effect: Failure to reconcile federal awards with expenditures, along with an incomplete and inaccurate SEFA, could lead to incorrect reporting of federal funds, misstatement of financial information, and noncompliance with federal requirements. This represents a potential risk for improper use of federal funds and an inability to meet compliance and reporting obligations. Additionally, the omission of federal awards from the June 30, 2023 SEFA resulted in noncompliance with federal reporting requirements and inaccurate representation of Solvista Health’s federal award activity. Identification as a Repeat Finding: Not a repeat finding. Recommendation: We recommend Solvista Health design and implement internal control procedures to reconcile federal awards with the expenditures and revenue received to ensure completeness and accuracy in financial reporting. Additionally, management should prepare and maintain an accurate SEFA in accordance with 2 CFR 200.510 to ensure proper documentation and compliance with federal reporting requirements. Additionally, we recommend that Solvista Health train appropriate personnel on the requirements related to federal award reconciliations and SEFA preparation to mitigate the risk of noncompliance in the future.

Categories

Reporting

Other Findings in this Audit

  • 570052 2024-015
    Material Weakness
  • 570053 2024-016
    Material Weakness
  • 570054 2024-018
    Significant Deficiency
  • 570055 2024-019
    Significant Deficiency
  • 570056 2024-019
    Significant Deficiency
  • 570057 2024-019
    Significant Deficiency
  • 570058 2024-020
    Significant Deficiency
  • 570059 2024-020
    Significant Deficiency
  • 570060 2024-020
    Significant Deficiency
  • 570061 2024-021
    Significant Deficiency
  • 570062 2024-022
    Significant Deficiency
  • 570063 2024-022
    Significant Deficiency
  • 570064 2024-022
    Significant Deficiency
  • 570065 2024-022
    Significant Deficiency
  • 570066 2024-023
    Significant Deficiency
  • 570067 2024-023
    Significant Deficiency
  • 570068 2024-023
    Significant Deficiency
  • 570069 2024-023
    Significant Deficiency
  • 570070 2024-024
    Significant Deficiency
  • 570071 2024-024
    Significant Deficiency
  • 570072 2024-025
    Significant Deficiency
  • 570073 2024-025
    Significant Deficiency
  • 570074 2024-026
    Significant Deficiency
  • 570075 2024-027
    Significant Deficiency
  • 570076 2024-027
    Significant Deficiency
  • 570077 2024-028
    Significant Deficiency
  • 570078 2024-029
    Significant Deficiency
  • 570079 2024-029
    Significant Deficiency
  • 570080 2024-029
    Significant Deficiency
  • 570081 2024-014
    Material Weakness
  • 570082 2024-014
    Material Weakness
  • 570083 2024-014
    Material Weakness
  • 570084 2024-014
    Material Weakness
  • 570085 2024-014
    Material Weakness
  • 570086 2024-014
    Material Weakness
  • 570087 2024-014
    Material Weakness
  • 570088 2024-014
    Material Weakness
  • 570089 2024-014
    Material Weakness
  • 570090 2024-014
    Material Weakness
  • 570091 2024-014
    Material Weakness
  • 570092 2024-014
    Material Weakness
  • 570093 2024-017
    Significant Deficiency
  • 570094 2024-017
    Significant Deficiency
  • 570095 2024-029
    Significant Deficiency
  • 1146494 2024-015
    Material Weakness
  • 1146495 2024-016
    Material Weakness
  • 1146496 2024-018
    Significant Deficiency
  • 1146497 2024-019
    Significant Deficiency
  • 1146498 2024-019
    Significant Deficiency
  • 1146499 2024-019
    Significant Deficiency
  • 1146500 2024-020
    Significant Deficiency
  • 1146501 2024-020
    Significant Deficiency
  • 1146502 2024-020
    Significant Deficiency
  • 1146503 2024-021
    Significant Deficiency
  • 1146504 2024-022
    Significant Deficiency
  • 1146505 2024-022
    Significant Deficiency
  • 1146506 2024-022
    Significant Deficiency
  • 1146507 2024-022
    Significant Deficiency
  • 1146508 2024-023
    Significant Deficiency
  • 1146509 2024-023
    Significant Deficiency
  • 1146510 2024-023
    Significant Deficiency
  • 1146511 2024-023
    Significant Deficiency
  • 1146512 2024-024
    Significant Deficiency
  • 1146513 2024-024
    Significant Deficiency
  • 1146514 2024-025
    Significant Deficiency
  • 1146515 2024-025
    Significant Deficiency
  • 1146516 2024-026
    Significant Deficiency
  • 1146517 2024-027
    Significant Deficiency
  • 1146518 2024-027
    Significant Deficiency
  • 1146519 2024-028
    Significant Deficiency
  • 1146520 2024-029
    Significant Deficiency
  • 1146521 2024-029
    Significant Deficiency
  • 1146522 2024-029
    Significant Deficiency
  • 1146523 2024-014
    Material Weakness
  • 1146524 2024-014
    Material Weakness
  • 1146525 2024-014
    Material Weakness
  • 1146526 2024-014
    Material Weakness
  • 1146527 2024-014
    Material Weakness
  • 1146528 2024-014
    Material Weakness
  • 1146529 2024-014
    Material Weakness
  • 1146530 2024-014
    Material Weakness
  • 1146531 2024-014
    Material Weakness
  • 1146532 2024-014
    Material Weakness
  • 1146533 2024-014
    Material Weakness
  • 1146534 2024-014
    Material Weakness
  • 1146535 2024-017
    Significant Deficiency
  • 1146537 2024-029
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.696 Certified Community Behavioral Health Clinic Expansion Grants $381,902
93.778 Medical Assistance Program $349,300
93.575 Child Care and Development Block Grant $334,148
21.027 Coronavirus State and Local Fiscal Recovery Funds $219,142
93.665 Emergency Grants to Address Mental and Substance Use Disorders During Covid-19 $124,108
16.745 Criminal and Juvenile Justice and Mental Health Collaboration Program $114,870
93.870 Maternal, Infant and Early Childhood Home Visiting Grant $75,205
93.958 Block Grants for Community Mental Health Services $20,000
93.069 Public Health Emergency Preparedness $10,300